Urologix (ULGX) Price & Analysis

7 Followers

ULGX Stock Chart & Stats

$0.02

$0.00(0.00%)

At close: Jun 24 4:00 PM EDT

$0.02

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.01 - $0.03

Previous CloseN/A

Volume13.50K

Average Volume (3M)500.00

Market Cap

$2.18K

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta27.18

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding21,817,726

10 Day Avg. Volume500

30 Day Avg. Volume500

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

ULGX FAQ

What was Urologix’s price range in the past 12 months?

Urologix lowest stock price was $0.01 and its highest was $0.03 in the past 12 months.

What is Urologix’s market cap?

Urologix’s market cap is $2.18K.

When is Urologix’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Urologix’s earnings last quarter?

Currently, no data Available

Is Urologix overvalued?

According to Wall Street analysts Urologix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Urologix pay dividends?

Urologix does not currently pay dividends.

What is Urologix’s EPS estimate?

Urologix’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Urologix have?

Urologix has 21,817,726 shares outstanding.

What happened to Urologix’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Urologix?

Currently, no hedge funds are holding shares in ULGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Urologix

Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company's innovative solutions target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Among its key offerings is Cooled ThermoTherapy, a system that precisely applies microwave energy while simultaneously employing a cooling mechanism to safeguard healthy tissues and improve patient comfort. Urologix also provides the Prostiva RF Therapy System, which directs radio frequency energy into the prostate gland. This process works to eliminate problematic prostatic tissue, consequently easing urethral constriction and alleviating BPH-related discomfort. Urologix, Inc. caters to both healthcare professionals and patients.